Sentiment-Signal
18,9
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (10.03.2026)
HOCH Abgang Schlüsselpersonen (10.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 10.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | GAAP results is provided in the press release. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 02.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
| 11.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appo |
| 05.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
| 07.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | AP results is provided in the press release. Item 5.02 Departure of Directors or Certain Officers; Election of Direct |
| 12.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appo |
| 03.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
Stammdaten
Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. The company was founded in 1972 and is headquartered in Lehi, Utah.
Unternehmen & Branche
| Name | NATURES SUNSHINE PRODUCTS INC |
|---|---|
| Ticker | NATR |
| CIK | 0000275053 |
| Boerse | US |
| Sektor | Consumer Defensive |
| Industrie | Packaged Foods |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 469,4 Mio. USD |
| Beta | 0,92 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 480,144,000 | 19,521,000 | 1.06 | 261,146,000 | |
| 2025-09-30 | 10-Q | 128,339,000 | 5,334,000 | 0.30 | 264,805,000 | |
| 2025-06-30 | 10-Q | 114,750,000 | 5,333,000 | 0.28 | 254,875,000 | |
| 2025-03-31 | 10-Q | 113,248,000 | 4,747,000 | 0.25 | 252,702,000 | |
| 2024-12-31 | 10-K | 454,364,000 | 7,696,000 | 0.40 | 240,855,000 | |
| 2024-09-30 | 10-Q | 114,615,000 | 4,347,000 | 0.23 | 245,333,000 | |
| 2024-06-30 | 10-Q | 110,551,000 | 1,349,000 | 0.07 | 235,831,000 | |
| 2024-03-31 | 10-Q | 110,993,000 | 2,321,000 | 0.12 | 247,267,000 | |
| 2023-12-31 | 10-K | 445,320,000 | 15,076,000 | 0.77 | 249,773,000 | |
| 2023-09-30 | 10-Q | 111,202,000 | 2,832,000 | 0.15 | 239,913,000 | |
| 2023-06-30 | 10-Q | 116,548,000 | 2,422,000 | 0.12 | 236,152,000 | |
| 2023-03-31 | 10-Q | 108,634,000 | 860,000 | 0.04 | 234,584,000 | |
| 2022-12-31 | 10-K | 421,910,000 | -390,000 | -0.02 | 229,778,000 | |
| 2022-09-30 | 10-Q | 104,506,000 | 90,000 | 0.00 | 223,508,000 | |
| 2022-06-30 | 10-Q | 104,161,000 | 516,000 | 0.03 | 233,059,000 | |
| 2022-03-31 | 10-Q | 110,494,000 | -2,950,000 | -0.15 | 238,662,000 | |
| 2021-12-31 | 10-K | 444,084,000 | 1.42 | 258,874,000 | ||
| 2021-09-30 | 10-Q | 114,746,000 | 4,858,000 | 0.24 | 239,752,000 | |
| 2021-06-30 | 10-Q | 108,978,000 | 6,540,000 | 0.32 | 233,190,000 | |
| 2021-03-31 | 10-Q | 102,421,000 | 4,016,000 | 0.20 | 245,831,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-13 | Yates Bryant J | Officer, EVP & President, Europe | Open Market Sale | -19,516 | 24.35 | -475,214.60 | -16,5% | |
| 2026-03-13 | Norman Daniel C | Officer, EVP & President, Asia | Open Market Sale | -15,383 | 24.52 | -377,191.16 | -13,1% | |
| 2026-03-13 | Lanoy Jonathan David | Officer, SVP, Chief Accounting Officer | Open Market Sale | -4,000 | 24.70 | -98,800.00 | -3,4% | |
| 2025-12-12 | Yates Bryant J | Officer, EVP & President, Europe | Open Market Sale | -1,700 | 22.29 | -37,893.00 | -1,3% | |
| 2025-11-18 | Lanoy Jonathan David | Officer, SVP, Chief Accounting Officer | Open Market Sale | -5,000 | 20.45 | -102,250.00 | -3,6% | |
| 2025-11-14 | Brower Nathan G | Officer, EVP, General Counsel | Open Market Sale | -3,800 | 20.81 | -79,078.00 | -2,8% | |
| 2025-11-12 | Norman Daniel C | Officer, EVP & President, Asia | Open Market Sale | -8,884 | 20.46 | -181,766.64 | -6,3% | |
| 2025-08-29 | Yates Bryant J | Officer, EVP & President, Europe | Open Market Sale | -4,672 | 16.71 | -78,069.12 | -2,7% | |
| 2025-08-26 | Yates Bryant J | Officer, EVP & President, Europe | Open Market Sale | -5,000 | 16.77 | -83,850.00 | -2,9% | |
| 2025-08-13 | Brower Nathan G | Officer, EVP, General Counsel | Open Market Sale | -9,996 | 16.54 | -165,333.84 | -5,8% | |
| 2025-08-13 | Lanoy Jonathan David | Officer, SVP, Chief Accounting Officer | Open Market Sale | -5,000 | 16.51 | -82,550.00 | -2,9% | |
| 2025-06-27 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% Owner | Open Market Sale | -2,854,607 | 11.46 | -32,713,796.22 | -1138,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.